Association between risk behaviors and antiretroviral resistance in HIV-infected patients receiving opioid agonist treatment

Journal of Addiction Medicine

Volumn 7, Issue 2, 2013, Pages 102-107

  Tetrault, Jeanette M ^a   Kozal, Michael J ^a,b   Chiarella, Jennifer ^a   Sullivan, Lynn E ^a,b   Dinh, An T ^a   Fiellin, David A ^a,b  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b YALE UNIVERSITY   (United States)

Author keywords

Buprenorphine; Drug resistance; HIV; Methadone; Risk taking; Viral

Indexed keywords

ANTIRETROVIRUS AGENT; BUPRENORPHINE; ILLICIT DRUG; METHADONE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; OPIATE AGONIST; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADULT; ARTICLE; CAUCASIAN; CROSS-SECTIONAL STUDY; DEMOGRAPHY; DISEASE TRANSMISSION; DRUG USE; FEMALE; GENOTYPE; HEALTH BEHAVIOR; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; PREVALENCE; PRIORITY JOURNAL; SELF REPORT; UNPROTECTED SEX; VIRUS LOAD;

ANALGESICS, OPIOID; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BUPRENORPHINE; CROSS-SECTIONAL STUDIES; DRUG RESISTANCE, VIRAL; FEMALE; HIV INFECTIONS; HUMANS; MALE; METHADONE; MIDDLE AGED; PREVALENCE; RISK-TAKING; SEXUAL BEHAVIOR; SUBSTANCE ABUSE, INTRAVENOUS;

EID: 84877978418     PISSN: 19320620     EISSN: 19353227     Source Type: Journal    
DOI: 10.1097/ADM.0b013e31827f9bdf     Document Type: Article

References (31)

1. Fisher JD, Cornman DH, Norton WE, Fisher WA. Involving behavioral scientists, health care providers, and HIV-infected patients as collaborators in theory-based HIV prevention and antiretroviral adherence interventions. JAIDS 2006;43(Suppl. 1):S10-S17.
2. Fisher JD, Fisher WA, Cornman DH, Amico RK, Bryan A, Friedland GH. Clinician-delivered intervention during routine clinical care reduces unprotected sexual behavior among HIV-infected patients. JAIDS 2006;41(1): 44-52.
3. Gowing L, Farrell MF, Bornemann R, Sullivan LE, Ali R. Oral substitution treatment of injecting opioid users for prevention of HIV infection. [Meta- Analysis Review]. Cochrane Database Syst Rev 2011;8:CD004145.
4. Korthuis PT, Tozzi MJ, Nandi V, et al. for the BHIVES Collaborative. Improved quality of life for opioid-dependent patients receiving buprenorphine treatment in HIV clinics. JAIDS 2011;56(Suppl. 1):S39-S45.
5. Kozal MJ. Drug-resistant human immunodefiency virus. Clin Microbiol Infect 2009;15(Suppl. 1): 69-73.
6. Kozal MJ, Amico KR, Chiarella J, et al. HIV drug resistance and HIV transmission risk behaviors among active injection drug users. JAIDS 2005;40(1): 106-109.
7. Kozal MJ, Amico KR, Chiarella J, et al. A population-based and longitudinal study of sexual behavior and multidrug-resistant HIV among patients in clinical care. Med Gen Med 2006;8(2): 72.
8. Kozal MJ, Amico KR, Chiarella J, et al. Antiretroviral resistance and high-risk transmission behavior among HIV-positive patients in clinical care. AIDS 2004;18(16): 2185-2189.
9. Kozal MJ, Chiarella J, St. John EP, et al. Prevalence of low-level HIV-1 variants with reverse transcriptase mutation K65R among different HIV subtypes and the effects of antiretroviral drug exposure on variant levels. Antivir Ther 2011;16(6): 925-929.
10. Kozal MJ, Hullsiek KH, Macarthur RD, et al. for Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA). The Incidence of HIV drug resistance and its impact on progression of HIV disease among antiretroviral-naive participants started on three different antiretroviral therapy strategies. HIV Clin Trials 2007;8(6): 357-370.
11. Kozal MJ, Shah N, Shen N, et al. Extensive polymorphisms observed in HIV-1 clade B protease gene using high-density oligonucleotide arrays. Nat Med 1996;2(7): 753-759.
12. Lataillade M, Chiarella J, Yang R, et al. Prevalence and clinical significance of HIV drug resistance mutations by ultra-deep sequencing in antiretroviralnaive subjects in the CASTLE study. PLoS ONE 2010;5(6):e10952.
13. Le T, Chiarella J, Simen BB, et al. Low-abundance HIV drug-resistant viral variants in treatment-experienced persons correlate with historical antiretroviral use. PLoS ONE 2009;4(6):e6079.
14. Li JZ, Paredes R, Ribaudo HJ, et al. Low-frequency HIV-1 drug resistance mutations and risk of NNRTI-based antiretroviral treatment failure: A systematic review and pooled analysis. JAMA 2011;305(13): 1327-1335.
15. Maru DS-R, Kozal MJ, Bruce RD, Springer SA, Altice FL. Directly administered antiretroviral therapy for HIV-infected drug users does not have an impact on antiretroviral resistance: Results from a randomized controlled trial. JAIDS 2007;46(5): 555-563.
16. McLellan AT, Luborsky L, Woody GE, O'Brien CP. An improved diagnostic evaluation instrument for substance abuse patients: The addiction severity index. J Nerv Ment Dis 1980;168(1): 26-33.
17. Metzger DS, Woody GE, McLellan AT, et al. Human immunodeficiency virus seroconversion among intravenous drug users in- and out-of-treatment: An 18-month prospective follow-up. JAIDS 1993;6(9): 1049-1056.
18. Metzger DS, Woody GE, O'Brien CP. Drug treatment as HIV prevention: A research update. JAIDS 2010;55(Suppl. 1):S32-S36.
19. Moatti JP, Carrieri MP, Spire B, Gastaut JA, Cassuto JP, Moreau J. Adherence to HAART in French HIV-infected injecting drug users: The contribution of buprenorphine drug maintenance treatment: The Manif 2000 study group. AIDS 2000;14(2): 151-155.
20. Novak RM, Chen L, MacArthur RD, et al. Prevalence of antiretroviral drug resistance mutations in chronically HIV-infected, treatment-naive patients: Implications for routine resistance screening before initiation of antiretroviral therapy. Clin Infect Dis 2005;40(3): 468-474.
21. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. 2011.
22. Rhee S-Y, Fessel WJ, Liu TF, et al. Predictive value of HIV-1 genotypic resistance test interpretation algorithms. J Infect Dis 2009;200(3): 453-463.
23. Simen BB, Simons JF, Hullsiek KH, et al. for Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA). Low-abundance drug-resistant viral variants in chronically HIV-infected, antiretroviral treatment-naive patients significantly impact treatment outcomes. J Infect Dis 2009;199(5): 693-701.
24. Simons JF, Egholm M, Lanza J, et al. Ultradeep sequencing of HIV clinical samples. Paper presented at the XIV International HIV Drug Resistance Workshop, Quebec City, Quebec, Canada, 2005.
25. Stanford University. HIV drug resistance database. 2009. Available at: http://hivdb. stanford. edu/. Accessed July 5, 2009.
26. Sullivan LE, Barry D, Moore BA, et al. A trial of integrated buprenorphine/naloxone and HIV clinical care. Clin Infect Dis 2006;43(Suppl. 4):S184-S190.
27. Sullivan LE, Metzger DS, Fudala PJ, Fiellin DA. Decreasing international HIV transmission: The role of expanding access to opioid agonist therapies for injection drug users. Addiction 2005;100(2): 150-158.
28. Sullivan LE, Moore BA, Chawarski MC, et al. Buprenorphine/naloxone treatment in primary care is associated with decreased human immunodeficiency virus risk behaviors. J Subst Abuse Treat 2008;35(1);87-92.
29. Sullivan LE, Moore BA, O'Connor PG, et al. The association between cocaine use and treatment outcomes in patients receiving office-based buprenorphine/naloxone for the treatment of opioid dependence. Am J Addict 2010;19(1): 53-58.
30. Terry Beirn Community Programs for Clinical Research on AIDS. Form 646: antiretroviral medication self-report. Available at http://sdmc. cpcra. org/CRFormsIndex. html#module. Accessed February 15, 2008.
31. World Health Organization. HIV/AIDS data and statistics. 2010. Available at: http://www. who. int/hiv/data. Accessed February 2, 2011.